

## Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

April 22, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 22, 2024-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company's website and will be available via the following link: <a href="https://edge.media-server.com/mmc/p/6m9ec99y">https://edge.media-server.com/mmc/p/6m9ec99y</a>. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at <a href="https://investor.veracvte.com/events-presentations">https://investor.veracvte.com/events-presentations</a>.

The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BI5ccb6c3c55e34500b5c9256eb8e1a7f4

## **About Veracyte**

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and Al capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit <a href="https://www.veracyte.com">www.veracyte.com</a> or follow us on <a href="https://www.veracyte.com">LinkedIn</a> or <a href="https://www.veracyte.com">X (Twitter)</a>.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240422296304/en/

Investors: Shayla Gorman investors@veracyte.com (619) 393-1545

Media: Tracy Morris media@veracyte.com (650) 380-4413

Source: Veracyte, Inc.